A new trading day began on Tuesday, with Allogene Therapeutics Inc (NASDAQ: ALLO) stock price down -5.07% from the previous day of trading, before settling in for the closing price of $1.38. ALLO’s price has ranged from $0.86 to $3.78 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 6.26% over the past five years. Meanwhile, its annual earnings per share averaged 29.47%. With a float of $160.22 million, this company’s outstanding shares have now reached $223.16 million.
Allogene Therapeutics Inc (ALLO) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Allogene Therapeutics Inc is 28.71%, while institutional ownership is 50.55%. The most recent insider transaction that took place on Nov 17 ’25, was worth 959. In this transaction SVP, Chief Technical Officer of this company sold 786 shares at a rate of $1.22, taking the stock ownership to the 217,721 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 786 for $1.22, making the entire transaction worth $959.
Allogene Therapeutics Inc (ALLO) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.28 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.39% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Here are Allogene Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (NASDAQ: ALLO) saw its 5-day average volume 2.69 million, a negative change from its year-to-date volume of 3.82 million. As of the previous 9 days, the stock’s Stochastic %D was 18.55%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 55.64%, which indicates a significant increase from 5.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0948 in the past 14 days, which was higher than the 0.0837 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3196, while its 200-day Moving Average is $1.2982. Nevertheless, the first resistance level for the watch stands at $1.3617 in the near term. At $1.4133, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4467. If the price goes on to break the first support level at $1.2767, it is likely to go to the next support level at $1.2433. The third support level lies at $1.1917 if the price breaches the second support level.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
With a market capitalization of 294.40 million, the company has a total of 224,730K Shares Outstanding. Currently, annual sales are 20 K while annual income is -257,590 K. The company’s previous quarter sales were 0 K while its latest quarter income was -41,400 K.
